PEPDEPO
← The Bible
Nootropic

Semax

A Russian nootropic peptide for focus, memory, and mental drive.

Emerging evidence

Overview

Semax is a synthetic nootropic peptide derived from a fragment of ACTH (adrenocorticotropic hormone). It was developed in Russia and has been used there clinically for neurological support; in the United States it is currently a research compound. How it works: Semax raises brain-derived neurotrophic factor (BDNF) and modulates the dopamine and serotonin systems. The result is support for focus, memory consolidation, and neuroprotection - without the harsh stimulant feel of caffeine or amphetamines. Who tends to use it: People whose primary goals are focus and memory, or those looking for a mental edge alongside mood support. It carries a secondary rating for energy and a strong primary rating for cognition. How it is taken: Semax is delivered intranasally - a few drops into the nostrils. The general range used in protocols is 300-600 mcg, dosed once or twice daily, in the morning or early afternoon. It is run in 2-4 week cycles with a break afterward. Dosing later in the day is not recommended because it can be stimulating and may interfere with sleep. What to expect: Users typically notice sharper mental clarity and improved drive. Because it raises BDNF, there may be a gradual neurological benefit over the course of a cycle, not just an immediate effect. Safety: Semax is generally well tolerated. The main practical caution is timing - avoid evening doses. It is approved in Russia as a prescription drug; in the US it is classified as a research compound and is not FDA-approved for any indication. Your licensed provider in the PepDepo network will review your goals and history at consult and set the exact dose and cycle structure that fits your situation.

At a glance

Route
Intranasal
Dose
300-600 mcg
Frequency
1-2x daily
Timing
Morning / early afternoon
Cycle
2-4 weeks on, break

Combining

Stacks well with: Selank

Safety

Well tolerated; avoid late dosing (can be stimulating).

Regulatory: Approved in Russia; research compound in the US.

Questions

How do I take Semax?

Semax is taken intranasally - drops applied inside the nostrils. The general range is 300-600 mcg, once or twice daily. Your clinician sets your exact dose at consult.

When during the day should I take it?

Morning or early afternoon. The record flags late dosing specifically because Semax can be stimulating, which may make it harder to fall asleep.

How long do I use it before taking a break?

Cycles run 2-4 weeks, followed by a break. Cycling helps maintain responsiveness and is the standard approach in the protocols where Semax is used.

What goals is Semax mainly used for?

Its primary use is cognition - focus and memory. It also carries a secondary rating for mood and a minor supportive role for energy.

Are there any contraindications I should know about?

No absolute contraindications appear in the current record. It is listed as well tolerated, with no excludeIf flags for pregnancy or cancer history. That said, this is an unlicensed research compound in the US, so full clinical history review at consult is standard before starting.

Is Semax legal?

It is approved as a prescription drug in Russia. In the United States it is a research compound - not FDA-approved for any indication. licensed provider in the PepDepo networks can discuss what that means for your specific situation.

Does Semax stack well with anything?

Yes - it pairs well with Selank. The two are often used together: Semax for drive and focus, Selank for calm and anxiety reduction.

Related protocols

Want a personalized protocol?

Exact dosing is set with a licensed provider in the PepDepo network. This page is education, not a prescription.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.